Don’t restrict Chinese biotech

Regulatory Friction and the Decoupling Hypothesis

John Moolenaar, chairman of the U.S. House Select Committee on China, has formally urged the U.S. Treasury to classify biotechnology as a prohibited technology. This proposal specifically cites the $15.2 billion partnership between Bristol Myers Squibb (BMS) and China’s Hengrui Pharma as a primary example of U.S. capital facilitating the expansion of Chinese R&D capabilities. The legislative intent is to limit the flow of technology and financing into an ecosystem that now accounts for nearly 30% of global drug development, according to data from Citeline.

We observe in the data a significant surge in Chinese biotechnological output over the last decade. Pharmaceutical and medical technology patent applications in China increased by 379%, supported by established R&D hubs in cities like Shanghai and Suzhou. These regions provide a dense infrastructure of skilled professionals and a supply chain that allows for rapid clinical trial enrollment at a lower cost-basis than Western counterparts. A forced decoupling could potentially disrupt the mechanistic progress of many early-stage longevity interventions that rely on these cost-effective validation pathways.

Comparative Efficacy and Clinical Integration

Despite the proposed restrictions, the clinical data suggests a high level of efficacy for Chinese-developed molecules, which continues to attract major U.S. pharmaceutical entities. A notable case is ivonescimab, an antibody developed by the Chinese firm Akeso. In a Phase III trial, ivonescimab demonstrated superior performance compared to Merck’s Keytruda, which is currently regarded as one of the industry's most successful immunotherapy products. Such findings underscore the objective quality of the research emerging from this cohort.

The scale of integration is reflected in the financial metrics provided by the National Medical Products Administration (NMPA). In 2025, the total value of out-licensing deals for innovative drugs from China reached $136 billion. This momentum has continued into 2026, with first-quarter transactions already surpassing $60 billion. Recent actions by industry leaders further complicate the narrative of decoupling; for instance, Pfizer recently entered a global licensing agreement with Innovent Biologics valued at up to $10.5 billion to develop 12 early-stage cancer medicines.

Assessment of Global Health Implications

The current evidence suggests that the biotech sectors of the U.S. and China are deeply intertwined through joint R&D and licensing agreements. These collaborations are frequently focused on difficult-to-treat conditions, including metabolic disorders, autoimmune diseases, and various cancers—areas central to the study of cellular aging and human performance optimization.

From an analytical perspective, the primary risk of increased investment restrictions is the potential slowing of therapeutic innovation. If U.S. drugmakers are restricted from the Chinese ecosystem, the resulting increase in R&D costs and trial durations may limit the number of viable compounds that reach the market. While the legislative focus remains on national security, the clinical reality is that the future of global public health and the advancement of longevity science currently depend on a highly integrated, cross-border research framework. We will continue to monitor the Treasury’s response to these legislative pressures, as the final classification of biotech will determine the accessibility of innovative therapies for the foreseeable future.